[{"to": "272", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is a proton pump inhibitor that suppresses gastric acid sec"}, {"to": "635", "prefix": "l sulphenamide. By acting specifically on the proton pump, ", "from": "624", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " blocks the final step in acid production, thus reducing gas"}, {"to": "1189", "prefix": "vity\n                           \nThe effect of intravenous ", "from": "1178", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " on intragastric pH was determined in two separate studies. "}, {"to": "1297", "prefix": "ined in two separate studies. In the first study, 20 mg of ", "from": "1279", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection was administered intravenously once daily at "}, {"to": "1504", "prefix": " were included in the study. In the second study, 40 mg of ", "from": "1486", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection was administered intravenously once daily at "}, {"to": "1976", "prefix": "                           \nIn oral studies, the effect of ", "from": "1955", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole magnesium", "suffix": " on serum gastrin concentrations was evaluated in approximat"}, {"to": "2814", "prefix": "\nThere are no data available on the effects of intravenous ", "from": "2803", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " on ECL cells.\n\n                           \nIn 24-month carc"}, {"to": "3709", "prefix": "                      \nIn over 1,000 patients treated with ", "from": "3688", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole magnesium", "suffix": " "}, {"to": "4037", "prefix": "             Endocrine Effects\n                           \n", "from": "4016", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole magnesium", "suffix": " had no effect on thyroid function when given in oral doses "}, {"to": "4167", "prefix": "oral doses of 20 mg or 40 mg for 4 weeks. Other effects of ", "from": "4146", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole magnesium", "suffix": " on the endocrine system were assessed using omeprazole stud"}, {"to": "4822", "prefix": "                           \nThe pharmacokinetic profile of ", "from": "4804", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection 20 mg and 40 mg was determined in 24 healthy "}, {"to": "5034", "prefix": " following once daily administration of 20 mg and 40 mg of ", "from": "5016", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection by constant rate over 30 minutes for five day"}, {"to": "5404", "prefix": "                  Distribution\n                           \n", "from": "5393", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is 97% bound to plasma proteins. Plasma protein binding is "}, {"to": "5727", "prefix": "                    Metabolism\n                           \n", "from": "5716", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is extensively metabolized in the liver by the cytochrome P"}, {"to": "5843", "prefix": " enzyme system. The metabolites of ", "from": "5832", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " lack antisecretory activity. The major part of esomeprazole"}, {"to": "6163", "prefix": "P2C19 isoenzyme exhibits polymorphism in the metabolism of ", "from": "6152", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ", since some 3% of Caucasians and 15 to 20% of Asians lack C"}, {"to": "6711", "prefix": "                     Excretion\n                           \n", "from": "6700", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is excreted as metabolites primarily in urine but also in f"}, {"to": "6843", "prefix": "ces. Less than 1% of parent drug is excreted in the urine. ", "from": "6832", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is completely eliminated from plasma, and there is no accum"}, {"to": "7005", "prefix": "istration. The plasma elimination half-life of intravenous ", "from": "6994", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is approximately 1.1 to 1.4 hours and is prolonged with inc"}, {"to": "7105", "prefix": "hours and is prolonged with increasing dose of intravenous ", "from": "7094", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n\n                           \n\n                           C"}, {"to": "7404", "prefix": " and ", "from": "7393", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": "  "}, {"to": "7995", "prefix": " and metabolizer status has been made previously with oral ", "from": "7984", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ". The pharmacokinetics of esomeprazole is not expected to be"}, {"to": "8033", "prefix": "previously with oral esomeprazole. The pharmacokinetics of ", "from": "8022", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is not expected to be affected differently by intrinsic or "}, {"to": "8287", "prefix": "tment in special populations are suggested for intravenous ", "from": "8276", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " as for oral esomeprazole.\n\n                           \n\n   "}, {"to": "8312", "prefix": "ons are suggested for intravenous esomeprazole as for oral ", "from": "8301", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n\n                           \n\n                           G"}, {"to": "8785", "prefix": "ndomized, open-label, multi-national, repeated dose study, ", "from": "8774", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " PK was evaluated following a once-daily 3-minute injection "}, {"to": "8923", "prefix": "tal of 50 pediatric patients 0 to 17 years old, inclusive. ", "from": "8912", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " plasma AUC values for 20 mg esomeprazole sodium for injecti"}, {"to": "8971", "prefix": "s old, inclusive. Esomeprazole plasma AUC values for 20 mg ", "from": "8953", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection were 183% and 60% higher in pediatric patient"}, {"to": "9528", "prefix": " to those observed in adult patients administered 20 mg of ", "from": "9510", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection once every 24 hours. Further, increasing the "}, {"to": "9798", "prefix": "to those observed in adult patients at the 40 mg and 20 mg ", "from": "9780", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection doses.\n\n                           \n\n        "}, {"to": "10103", "prefix": "fferences have been seen for intravenous administration of ", "from": "10092", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ". Dosage adjustment based on gender is not necessary.\n\n     "}, {"to": "10330", "prefix": "    \nIn oral studies, the steady state pharmacokinetics of ", "from": "10319", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " obtained after administration of 40 mg once daily to 4 pati"}, {"to": "11385", "prefix": "ciency\n                           \nThe pharmacokinetics of ", "from": "11374", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " in patients with renal impairment are not expected to be al"}, {"to": "11513", "prefix": " altered relative to healthy volunteers as less than 1% of ", "from": "11502", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is excreted unchanged in urine.\n                     \n     "}, {"to": "447", "prefix": "Pase in the gastric parietal cell. The S- and R-isomers of ", "from": "438", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " are protonated and converted in the acidic compartment of t"}, {"to": "2912", "prefix": "              \nIn 24-month carcinogenicity studies of oral ", "from": "2903", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " in rats, a dose-related significant occurrence of gastric E"}, {"to": "3416", "prefix": "obtained from more than 3,000 patients treated orally with ", "from": "3407", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " in long-term clinical trials. The incidence of ECL cell hyp"}, {"to": "4222", "prefix": "zole magnesium on the endocrine system were assessed using ", "from": "4213", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " studies. Omeprazole given in oral doses of 30 mg or 40 mg f"}, {"to": "4242", "prefix": "e endocrine system were assessed using omeprazole studies. ", "from": "4233", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": " given in oral doses of 30 mg or 40 mg for 2 to 4 weeks had "}, {"to": "4381", "prefix": "o effect on carbohydrate metabolism, circulating levels of ", "from": "4363", "name": "Parathyroid Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D010281", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "parathyroid hormone", "suffix": ", cortisol, estradiol, testosterone, prolactin, cholecystoki"}, {"to": "4391", "prefix": "ate metabolism, circulating levels of parathyroid hormone, ", "from": "4384", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cortisol", "suffix": ", estradiol, testosterone, prolactin, cholecystokinin or sec"}, {"to": "4402", "prefix": "lism, circulating levels of parathyroid hormone, cortisol, ", "from": "4394", "name": "Estradiol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004958", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "estradiol", "suffix": ", testosterone, prolactin, cholecystokinin or secretin.\n    "}, {"to": "4416", "prefix": "lating levels of parathyroid hormone, cortisol, estradiol, ", "from": "4405", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "testosterone", "suffix": ", prolactin, cholecystokinin or secretin.\n                  "}, {"to": "4427", "prefix": "of parathyroid hormone, cortisol, estradiol, testosterone, ", "from": "4419", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prolactin", "suffix": ", cholecystokinin or secretin.\n                     \n       "}, {"to": "4444", "prefix": "oid hormone, cortisol, estradiol, testosterone, prolactin, ", "from": "4430", "name": "Cholecystokinin", "fullId": "http://purl.bioontology.org/ontology/MESH/D002766", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cholecystokinin", "suffix": " or secretin.\n                     \n                     \n  "}, {"to": "4456", "prefix": "ol, estradiol, testosterone, prolactin, cholecystokinin or ", "from": "4449", "name": "Secretin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9627", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "secretin", "suffix": ".\n                     \n                     \n              "}, {"to": "7196", "prefix": "         \n\n                           Concomitant Use with ", "from": "7186", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": "\n                           \nResults from a crossover study "}, {"to": "7336", "prefix": " subjects have shown a pharmacokinetic interaction between ", "from": "7326", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " "}, {"to": "7511", "prefix": "nistered for 30 days. Exposure to the active metabolite of ", "from": "7501", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " was reduced by 35% to 40% over this time period. Pharmacody"}, {"to": "7734", "prefix": "t aggregation was related to the change in the exposure to ", "from": "7724", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " active metabolite.\n\n                           \n\n          "}, {"to": "274", "prefix": " of Action\n\n                     \n                         ", "from": "264", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " is a selective 5-HT3 receptor antagonist. While ondansetron"}, {"to": "334", "prefix": "ndansetron is a selective 5-HT3 receptor antagonist. While ", "from": "324", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": "'s mechanism of action has not been fully characterized, it "}, {"to": "1046", "prefix": "ms after 15 minute intravenous infusions of 32 mg and 8 mg ", "from": "1036", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": ", respectively. A significant exposure-response relationship"}, {"to": "1141", "prefix": "cant exposure-response relationship was identified between ", "from": "1131", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " concentration and "}, {"to": "1594", "prefix": "kg of ", "from": "1584", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " had no effect on esophageal motility, gastric motility, low"}, {"to": "1963", "prefix": ". Multiday administration of ", "from": "1953", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " has been shown to slow colonic transit in normal volunteers"}, {"to": "2036", "prefix": "s been shown to slow colonic transit in normal volunteers. ", "from": "2026", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " has no effect on plasma prolactin concentrations. In a gend"}, {"to": "2151", "prefix": ", ", "from": "2141", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " 4 mg administered intravenously or intramuscularly was dyna"}, {"to": "3890", "prefix": "                   Distribution: Plasma protein binding of ", "from": "3880", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " as measured in vitro was 70% to 76%, over the pharmacologic"}, {"to": "4366", "prefix": "             \n                                 Metabolism: ", "from": "4356", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " is extensively metabolized in humans, with approximately 5%"}, {"to": "4849", "prefix": " to significantly contribute to the biological activity of ", "from": "4839", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ". The metabolites are observed in the urine.\n\n              "}, {"to": "4981", "prefix": "               In vitro metabolism studies have shown that ", "from": "4971", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is a substrate for multiple human hepatic cytochrome P-450 "}, {"to": "5119", "prefix": " including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ", "from": "5109", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " turnover, CYP3A4 plays a predominant role while formation o"}, {"to": "5278", "prefix": "es is apparently mediated by CYP1A2. The role of CYP2D6 in ", "from": "5268", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " in vivo metabolism is relatively minor.\n\n                  "}, {"to": "5398", "prefix": "                       The pharmacokinetics of intravenous ", "from": "5388", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " did not differ between subjects who were poor metabolisers "}, {"to": "5581", "prefix": "f CYP2D6, further supporting the limited role of CYP2D6 in ", "from": "5571", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " disposition in vivo.\n\n                           \n         "}, {"to": "5961", "prefix": "           Elimination: In adult cancer patients, the mean ", "from": "5951", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " elimination half-life was 4.0 hours, and there was no diffe"}, {"to": "6156", "prefix": " dose proportionality study, systemic exposure to 32 mg of ", "from": "6146", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " was not proportional to dose as measured by comparing dose-"}, {"to": "7532", "prefix": "kg of intravenous ", "from": "7522", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " every 4 hours for 3 doses during a safety and efficacy tria"}, {"to": "7778", "prefix": "kg of intravenous ", "from": "7768", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " prior to surgery with general anesthesia, and a population "}, {"to": "8260", "prefix": "kg of intravenous ", "from": "8250", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " every 4 hours for 3 doses would be expected to achieve a sy"}, {"to": "8691", "prefix": "ion of 45 minutes to 2 hours, a single intravenous dose of ", "from": "8681", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ", 2 mg "}, {"to": "9300", "prefix": "requiring general anesthesia, a single intravenous dose of ", "from": "9290", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ", 0.1 or 0.2 mg"}, {"to": "9753", "prefix": "atric patients younger than 18 years tend to have a higher ", "from": "9743", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " clearance compared to adults leading to a shorter half-life"}, {"to": "10137", "prefix": "kg of ", "from": "10127", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " at 4-hour intervals, patients older than 15 years of age ex"}, {"to": "10216", "prefix": "r intervals, patients older than 15 years of age exhibited ", "from": "10206", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " pharmacokinetic parameters similar to those of adults.\n\n   "}, {"to": "10770", "prefix": "expected to significantly influence the total clearance of ", "from": "10760", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ". However, ondansetron mean plasma clearance was reduced by "}, {"to": "10792", "prefix": "tly influence the total clearance of ondansetron. However, ", "from": "10782", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " mean plasma clearance was reduced by about 41% in patients "}, {"to": "411", "prefix": "sm of action has not been fully characterized, it is not a ", "from": "404", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "dopamine", "suffix": "-receptor antagonist.\n\n                     \n               "}, {"to": "2070", "prefix": " in normal volunteers. Ondansetron has no effect on plasma ", "from": "2062", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "prolactin", "suffix": " concentrations. In a gender-balanced pharmacodynamic study "}, {"to": "3424", "prefix": "mL ", "from": "3420", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "at 10", "suffix": " minutes after intravenous infusion and 31.9 [95% CI 26.3, 3"}, {"to": "4559", "prefix": "ine. The primary metabolic pathway is hydroxylation on the ", "from": "4554", "name": "indole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311224", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "indole", "suffix": " ring followed by subsequent glucuronide or sulfate conjugat"}, {"to": "10892", "prefix": "", "from": "10883", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "creatinine", "suffix": " clearance "}, {"to": "309", "prefix": "                    HARVONI is a fixed-dose combination of ", "from": "300", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir which are direct-acting antiviral agents aga"}, {"to": "1007", "prefix": "               Thorough QT studies have been conducted for ", "from": "998", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir.\n                              The effect of"}, {"to": "1078", "prefix": "nd sofosbuvir.\n                              The effect of ", "from": "1069", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " 120 mg twice daily "}, {"to": "1425", "prefix": ", ", "from": "1416", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " does not prolong QTc interval to any clinically relevant ex"}, {"to": "2530", "prefix": "                         The pharmacokinetic properties of ", "from": "2521", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and the predominant circulating metabolite GS-"}, {"to": "2737", "prefix": "nic hepatitis C. Following oral administration of HARVONI, ", "from": "2728", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " median peak concentrations were observed 4 to 4.5 hours pos"}, {"to": "3165", "prefix": "24 for ", "from": "3156", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " "}, {"to": "3304", "prefix": "mL, respectively. Steady-state Cmax for ", "from": "3295", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 were 323, 618, and 707 ng"}, {"to": "3538", "prefix": ", ", "from": "3529", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " AUC0"}, {"to": "4312", "prefix": "tly affect sofosbuvir Cmax. The exposures of GS-331007 and ", "from": "4303", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were not altered in the presence of either meal type. The r"}, {"to": "4924", "prefix": "                            \n                              ", "from": "4915", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is "}, {"to": "5012", "prefix": " human plasma proteins. After a single 90 mg dose of [14C]-", "from": "5003", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in healthy subjects, the blood to plasma ratio of 14C-radio"}, {"to": "5913", "prefix": "                     In vitro, no detectable metabolism of ", "from": "5904", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " was observed by human CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2"}, {"to": "6121", "prefix": "has been observed.  Following a single dose of 90 mg [14C]-", "from": "6112", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", systemic exposure was almost exclusively to the parent dru"}, {"to": "6212", "prefix": ".  Unchanged ", "from": "6203", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is the major species present in feces.\n                    "}, {"to": "7445", "prefix": "               Following a single 90 mg oral dose of [14C]-", "from": "7436", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", mean total recovery of the [14C]-radioactivity in feces an"}, {"to": "7632", "prefix": ". Unchanged ", "from": "7623", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " excreted in feces accounted for a mean of 70% of the admini"}, {"to": "7835", "prefix": "e. These data indicate that biliary excretion of unchanged ", "from": "7826", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is a major route of elimination, with renal excretion being"}, {"to": "7976", "prefix": ".  The median terminal half-life of ", "from": "7967", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " following administration of HARVONI was 47 hours.\n         "}, {"to": "9319", "prefix": "  Patients with Renal Impairment:  The pharmacokinetics of ", "from": "9310", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were studied with a single dose of 90 mg ledipasvir in HCV "}, {"to": "9371", "prefix": "ics of ledipasvir were studied with a single dose of 90 mg ", "from": "9362", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in HCV negative subjects with severe renal impairment "}, {"to": "9512", "prefix": ". No clinically relevant differences in ", "from": "9503", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " pharmacokinetics were observed between healthy subjects and"}, {"to": "11194", "prefix": " race had no clinically relevant effect on the exposure of ", "from": "11185", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007.\n                               "}, {"to": "11785", "prefix": " the exposure of sofosbuvir and GS-331007. AUC and Cmax of ", "from": "11776", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were 77% and 58% higher, respectively, in females than male"}, {"to": "11903", "prefix": "s than males; however, the relationship between gender and ", "from": "11894", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " exposures was not considered clinically relevant, as high r"}, {"to": "12534", "prefix": "              Pediatric Patients:  The pharmacokinetics of ", "from": "12525", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir in pediatric patients has not been establishe"}, {"to": "13218", "prefix": "d not have a clinically relevant effect on the exposure to ", "from": "13209", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 [see Use in Specific Populations"}, {"to": "13721", "prefix": "Patients with Hepatic Impairment:  The pharmacokinetics of ", "from": "13712", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were studied with a single dose of 90 mg ledipasvir in HCV "}, {"to": "13773", "prefix": "ics of ledipasvir were studied with a single dose of 90 mg ", "from": "13764", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in HCV negative subjects with severe hepatic impairment "}, {"to": "13862", "prefix": ". ", "from": "13853", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " plasma exposure "}, {"to": "14146", "prefix": "hosis had no clinically relevant effect on the exposure of ", "from": "14137", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " [see Use in Specific Populations "}, {"to": "15293", "prefix": "                            \n                              ", "from": "15284", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " and sofosbuvir are substrates of drug transporters P-gp and"}, {"to": "15456", "prefix": " may decrease ", "from": "15447", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir plasma concentrations, leading to reduced th"}, {"to": "15727", "prefix": "or BCRP may increase ", "from": "15718", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir plasma concentrations without increasing GS-"}, {"to": "15898", "prefix": "or BCRP inhibitors. Neither ", "from": "15889", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " nor sofosbuvir is a substrate for hepatic uptake transporte"}, {"to": "16168", "prefix": "nic cation transporter OCT2.\n                              ", "from": "16159", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is subject to slow oxidative metabolism via an unknown mech"}, {"to": "16283", "prefix": "n unknown mechanism. In vitro, no detectable metabolism of ", "from": "16274", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " by CYP enzymes has been observed. Biliary excretion of unch"}, {"to": "16359", "prefix": " enzymes has been observed. Biliary excretion of unchanged ", "from": "16350", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is a major route of elimination.  Sofosbuvir is not a subst"}, {"to": "16653", "prefix": "    The effects of coadministered drugs on the exposure of ", "from": "16644", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 are shown in Table 4 [see Drug I"}, {"to": "16888", "prefix": "         \n\n\nNo effect on the pharmacokinetic parameters of ", "from": "16879", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 was observed with the combinatio"}, {"to": "17083", "prefix": "enofovir DF, or raltegravir.\n                              ", "from": "17074", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of drug transporter P-gp and breast cancer "}, {"to": "17271", "prefix": "ption of coadministered substrates for these transporters. ", "from": "17262", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of transporters OATP1B1, OATP1B3, and BSEP "}, {"to": "17401", "prefix": "nly at concentrations exceeding those achieved in clinic.  ", "from": "17392", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is not an inhibitor of transporters MRP2, MRP4, OCT2, OAT1,"}, {"to": "17534", "prefix": "3, MATE1, and OCT1. The drug-drug interaction potential of ", "from": "17525", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is primarily limited to the intestinal inhibition of P-gp a"}, {"to": "17659", "prefix": "gp and BCRP. Clinically relevant transporter inhibition by ", "from": "17650", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in the systemic circulation is not expected due to its high"}, {"to": "17954", "prefix": "or of OAT1, OCT2, and MATE1.\n                              ", "from": "17945", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": ", sofosbuvir, and GS-331007 are not inhibitors or inducers o"}, {"to": "18094", "prefix": "T1A1 enzymes.\n                              The effects of ", "from": "18085", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir on the exposure of coadministered drugs are s"}, {"to": "18408", "prefix": "rs of the following coadministered drugs was observed with ", "from": "18399", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir: abacavir, cyclosporine, darunavir"}, {"to": "19099", "prefix": "                            \n                              ", "from": "19090", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of the HCV NS5A protein, which is required "}, {"to": "19267", "prefix": "tion in cell culture and cross-resistance studies indicate ", "from": "19258", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " targets NS5A as its mode of action.\n                       "}, {"to": "20417", "prefix": "                In HCV replicon assays, the EC50 values of ", "from": "20408", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " against full-length replicons from genotypes 1a and 1b were"}, {"to": "20552", "prefix": " nM and 0.004 nM, respectively.  The median EC50 values of ", "from": "20543", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " against chimeric replicons encoding NS5A sequences from cli"}, {"to": "20754", "prefix": ". ", "from": "20745", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " has less antiviral activity compared to genotype 1 against "}, {"to": "20914", "prefix": "EC50 values of 0.39 nM, 0.15 nM, and 1.1 nM, respectively. ", "from": "20905", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " has substantially lower activity against genotypes 2a, 2b, "}, {"to": "21800", "prefix": "respectively. Evaluation of sofosbuvir in combination with ", "from": "21791", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " showed no antagonistic effect in reducing HCV RNA levels in"}, {"to": "22654", "prefix": "              HCV replicons with reduced susceptibility to ", "from": "22645", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " have been selected in cell culture for genotypes 1a and 1b."}, {"to": "22751", "prefix": "culture for genotypes 1a and 1b. Reduced susceptibility to ", "from": "22742", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " was associated with the primary NS5A amino acid substitutio"}, {"to": "23092", "prefix": "ype 1a, conferred high levels of reduced susceptibility to ", "from": "23083", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " "}, {"to": "25637", "prefix": "243-fold reduced susceptibility to ", "from": "25628", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ".\n                                    Treatment-emergent NS5"}, {"to": "27074", "prefix": "                            \n                              ", "from": "27065", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " was fully active against the sofosbuvir resistance-associat"}, {"to": "27184", "prefix": "resistance-associated substitution S282T in NS5B while all ", "from": "27175", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " resistance-associated substitutions in NS5A were fully susc"}, {"to": "27297", "prefix": " were fully susceptible to sofosbuvir. Both sofosbuvir and ", "from": "27288", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were fully active against substitutions associated with res"}, {"to": "27570", "prefix": "se inhibitors. NS5A substitutions conferring resistance to ", "from": "27561", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " may reduce the antiviral activity of other NS5A inhibitors."}, {"to": "27657", "prefix": "tiviral activity of other NS5A inhibitors. The efficacy of ", "from": "27648", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ""}, {"to": "28259", "prefix": "               No data are available on the persistence of ", "from": "28250", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir resistance-associated substitutions. NS5A res"}, {"to": "324", "prefix": "     HARVONI is a fixed-dose combination of ledipasvir and ", "from": "315", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " which are direct-acting antiviral agents against the hepati"}, {"to": "1022", "prefix": "Thorough QT studies have been conducted for ledipasvir and ", "from": "1013", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ".\n                              The effect of ledipasvir 120"}, {"to": "1545", "prefix": "levant extent.\n                              The effect of ", "from": "1536", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " 400 mg "}, {"to": "1879", "prefix": "jects. At a dose three times the maximum recommended dose, ", "from": "1870", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " does not prolong QTc to any clinically relevant extent.\n   "}, {"to": "2542", "prefix": "             The pharmacokinetic properties of ledipasvir, ", "from": "2533", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and the predominant circulating metabolite GS-331007 have "}, {"to": "2815", "prefix": "eak concentrations were observed 4 to 4.5 hours post-dose. ", "from": "2806", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " was absorbed quickly and the peak median plasma concentrati"}, {"to": "3186", "prefix": ", ", "from": "3177", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " "}, {"to": "3316", "prefix": "mL, respectively. Steady-state Cmax for ledipasvir, ", "from": "3307", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 were 323, 618, and 707 ng"}, {"to": "3386", "prefix": "mL, respectively. ", "from": "3377", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " and GS-331007 AUC0"}, {"to": "4186", "prefix": " meal increased ", "from": "4177", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " AUC0"}, {"to": "4264", "prefix": " by approximately 2-fold, but did not significantly affect ", "from": "4255", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " Cmax. The exposures of GS-331007 and ledipasvir were not al"}, {"to": "5151", "prefix": "anged between 0.51 and 0.66.\n                              ", "from": "5142", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is approximately 61"}, {"to": "5403", "prefix": "nimal in human plasma. After a single 400 mg dose of [14C]-", "from": "5394", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in healthy subjects, the blood to plasma ratio of 14C-radio"}, {"to": "6292", "prefix": "or species present in feces.\n                              ", "from": "6283", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is extensively metabolized in the liver to form the pharmac"}, {"to": "6947", "prefix": "ctivity in vitro. After a single 400 mg oral dose of [14C]-", "from": "6938", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", GS-331007 accounted for approximately "}, {"to": "8112", "prefix": "              Following a single 400 mg oral dose of [14C]-", "from": "8103", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", mean total recovery of the dose was greater than 92%, cons"}, {"to": "8303", "prefix": " feces, and expired air, respectively. The majority of the ", "from": "8294", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " dose recovered in urine was GS-331007 "}, {"to": "8386", "prefix": " while 3.5% was recovered as ", "from": "8377", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". These data indicate that renal clearance is the major elim"}, {"to": "8521", "prefix": "n pathway for GS-331007. The median terminal half-lives of ", "from": "8512", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007 following administration of HARVONI were 0.5 "}, {"to": "9682", "prefix": "                                   The pharmacokinetics of ", "from": "9673", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " were studied in HCV negative subjects with mild "}, {"to": "9948", "prefix": "D requiring hemodialysis following a single 400 mg dose of ", "from": "9939", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". Relative to subjects with normal renal function "}, {"to": "10038", "prefix": ", the ", "from": "10029", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " AUC0"}, {"to": "10283", "prefix": "ith ESRD, relative to subjects with normal renal function, ", "from": "10274", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007 AUC0"}, {"to": "10347", "prefix": "inf was 28% and 1280% higher when ", "from": "10338", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " was dosed 1 hour before hemodialysis compared with 60% and "}, {"to": "10435", "prefix": "efore hemodialysis compared with 60% and 2070% higher when ", "from": "10426", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " was dosed 1 hour after hemodialysis, respectively. A 4 hour"}, {"to": "11206", "prefix": " clinically relevant effect on the exposure of ledipasvir, ", "from": "11197", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007.\n                                 \n         "}, {"to": "11743", "prefix": "ender had no clinically relevant effect on the exposure of ", "from": "11734", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007. AUC and Cmax of ledipasvir were 77% and 58% "}, {"to": "12548", "prefix": "Pediatric Patients:  The pharmacokinetics of ledipasvir or ", "from": "12539", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in pediatric patients has not been established [see Use in "}, {"to": "13230", "prefix": " clinically relevant effect on the exposure to ledipasvir, ", "from": "13221", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 [see Use in Specific Populations "}, {"to": "14258", "prefix": "                                   The pharmacokinetics of ", "from": "14249", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " were studied following 7-day dosing of 400 mg sofosbuvir in"}, {"to": "14315", "prefix": "f sofosbuvir were studied following 7-day dosing of 400 mg ", "from": "14306", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in HCV-infected subjects with moderate and severe hepatic i"}, {"to": "14478", "prefix": ". Relative to subjects with normal hepatic function, the ", "from": "14469", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " AUC0"}, {"to": "14772", "prefix": "hosis had no clinically relevant effect on the exposure of ", "from": "14763", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007 [see Use in Specific Populations "}, {"to": "15308", "prefix": "             \n                              Ledipasvir and ", "from": "15299", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " are substrates of drug transporters P-gp and BCRP while GS-"}, {"to": "15471", "prefix": " may decrease ledipasvir and ", "from": "15462", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " plasma concentrations, leading to reduced therapeutic effec"}, {"to": "15742", "prefix": "or BCRP may increase ledipasvir and ", "from": "15733", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " plasma concentrations without increasing GS-331007 plasma c"}, {"to": "15913", "prefix": "or BCRP inhibitors. Neither ledipasvir nor ", "from": "15904", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " is a substrate for hepatic uptake transporters OCT1, OATP1B"}, {"to": "16404", "prefix": " of unchanged ledipasvir is a major route of elimination.  ", "from": "16395", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is not a substrate for CYP and UGT1A1 enzymes. Clinically s"}, {"to": "16665", "prefix": "cts of coadministered drugs on the exposure of ledipasvir, ", "from": "16656", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 are shown in Table 4 [see Drug Interactions "}, {"to": "16900", "prefix": "No effect on the pharmacokinetic parameters of ledipasvir, ", "from": "16891", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 was observed with the combination of abacavi"}, {"to": "17747", "prefix": "rculation is not expected due to its high protein binding. ", "from": "17738", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " and GS-331007 are not inhibitors of drug transporters P-gp,"}, {"to": "17966", "prefix": "OCT2, and MATE1.\n                              Ledipasvir, ", "from": "17957", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 are not inhibitors or inducers of CYP or UGT"}, {"to": "18108", "prefix": "                              The effects of ledipasvir or ", "from": "18099", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " on the exposure of coadministered drugs are shown in Table "}, {"to": "18422", "prefix": "owing coadministered drugs was observed with ledipasvir or ", "from": "18413", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ": abacavir, cyclosporine, darunavir"}, {"to": "19344", "prefix": " NS5A as its mode of action.\n                              ", "from": "19335", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is an inhibitor of the HCV NS5B RNA-dependent RNA polymeras"}, {"to": "19458", "prefix": "t RNA polymerase, which is required for viral replication. ", "from": "19449", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is a nucleotide prodrug that undergoes intracellular metabo"}, {"to": "21144", "prefix": "                In HCV replicon assays, the EC50 values of ", "from": "21135", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " against full-length replicons from genotypes 1a, 1b, 2a, 3a"}, {"to": "21341", "prefix": "110 nM. The median EC50 value of ", "from": "21332", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " against chimeric replicons encoding NS5B sequences from cli"}, {"to": "21680", "prefix": " In replication competent virus assays, the EC50 values of ", "from": "21671", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " against genotypes 1a and 2a were 30 nM and 20 nM, respectiv"}, {"to": "21769", "prefix": "a and 2a were 30 nM and 20 nM, respectively. Evaluation of ", "from": "21760", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in combination with ledipasvir showed no antagonistic effec"}, {"to": "23230", "prefix": "              HCV replicons with reduced susceptibility to ", "from": "23221", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " have been selected in cell culture for multiple genotypes i"}, {"to": "23367", "prefix": " 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Reduced susceptibility to ", "from": "23358", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " was associated with the primary NS5B substitution S282T in "}, {"to": "23600", "prefix": "enotypes conferred 2- to 18-fold reduced susceptibility to ", "from": "23591", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ".\n                                 \n                        "}, {"to": "25776", "prefix": " previously associated with ", "from": "25767", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " failure were detected in the Phase 3 trials. In addition, N"}, {"to": "26291", "prefix": "currently unknown.\n                                    The ", "from": "26282", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": "-associated resistance substitution S282T in NS5B was not de"}, {"to": "27114", "prefix": "                   Ledipasvir was fully active against the ", "from": "27105", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " resistance-associated substitution S282T in NS5B while all "}, {"to": "27265", "prefix": "associated substitutions in NS5A were fully susceptible to ", "from": "27256", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". Both sofosbuvir and ledipasvir were fully active against s"}, {"to": "27282", "prefix": "tutions in NS5A were fully susceptible to sofosbuvir. Both ", "from": "27273", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and ledipasvir were fully active against substitutions asso"}, {"to": "27668", "prefix": "", "from": "27659", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " has not been established in patients who have previously fa"}, {"to": "28273", "prefix": " No data are available on the persistence of ledipasvir or ", "from": "28264", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " resistance-associated substitutions. NS5A resistance-associ"}, {"to": "30566", "prefix": "ociated with resistance to NS5B nucleoside inhibitors. The ", "from": "30557", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " resistance-associated substitution S282T was not detected i"}, {"to": "1261", "prefix": "", "from": "1250", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "moxifloxacin", "suffix": " 400 mg"}, {"to": "1744", "prefix": "", "from": "1733", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "moxifloxacin", "suffix": " 400 mg"}, {"to": "6613", "prefix": " and phosphoramidate cleavage by ", "from": "6605", "name": "Histidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006639", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "histidine", "suffix": " triad nucleotide-binding protein 1 "}, {"to": "6702", "prefix": " followed by phosphorylation by the ", "from": "6693", "name": "pyrimidine", "fullId": "http://purl.bioontology.org/ontology/MESH/C030986", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "pyrimidine", "suffix": " nucleotide biosynthesis pathway. Dephosphorylation results "}, {"to": "15412", "prefix": "e.g., ", "from": "15405", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rifampin", "suffix": " or St. John's wort"}, {"to": "16961", "prefix": "sbuvir, and GS-331007 was observed with the combination of ", "from": "16954", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "abacavir", "suffix": " and lamivudine, or emtricitabine, rilpivirine, and tenofovi"}, {"to": "18432", "prefix": "nistered drugs was observed with ledipasvir or sofosbuvir: ", "from": "18425", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "abacavir", "suffix": ", cyclosporine, darunavir"}, {"to": "16976", "prefix": "S-331007 was observed with the combination of abacavir and ", "from": "16967", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "lamivudine", "suffix": ", or emtricitabine, rilpivirine, and tenofovir DF, or ralteg"}, {"to": "18505", "prefix": "ritonavir, efavirenz, emtricitabine, ", "from": "18496", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "lamivudine", "suffix": ", methadone, or rilpivirine.\n                           \n   "}, {"to": "16994", "prefix": "served with the combination of abacavir and lamivudine, or ", "from": "16982", "name": "emtricitabine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/276237", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "emtricitabine", "suffix": ", rilpivirine, and tenofovir DF, or raltegravir.\n           "}, {"to": "18493", "prefix": "ritonavir, efavirenz, ", "from": "18481", "name": "emtricitabine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/276237", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "emtricitabine", "suffix": ", lamivudine, methadone, or rilpivirine.\n                   "}, {"to": "17007", "prefix": " combination of abacavir and lamivudine, or emtricitabine, ", "from": "16997", "name": "Rilpivirine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102270", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rilpivirine", "suffix": ", and tenofovir DF, or raltegravir.\n                        "}, {"to": "18532", "prefix": "navir, efavirenz, emtricitabine, lamivudine, methadone, or ", "from": "18522", "name": "Rilpivirine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102270", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rilpivirine", "suffix": ".\n                           \n                           \n  "}, {"to": "17022", "prefix": "bacavir and lamivudine, or emtricitabine, rilpivirine, and ", "from": "17014", "name": "tenofovir", "fullId": "http://purl.bioontology.org/ontology/MESH/C096918", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "tenofovir", "suffix": " DF, or raltegravir.\n                              Ledipasvi"}, {"to": "17041", "prefix": "udine, or emtricitabine, rilpivirine, and tenofovir DF, or ", "from": "17031", "name": "raltegravir", "fullId": "http://purl.bioontology.org/ontology/MESH/C507898", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "raltegravir", "suffix": ".\n                              Ledipasvir is an inhibitor o"}, {"to": "18446", "prefix": "rugs was observed with ledipasvir or sofosbuvir: abacavir, ", "from": "18435", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "cyclosporine", "suffix": ", darunavir"}, {"to": "18457", "prefix": "ved with ledipasvir or sofosbuvir: abacavir, cyclosporine, ", "from": "18449", "name": "darunavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C482292", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "darunavir", "suffix": ""}, {"to": "18467", "prefix": "", "from": "18459", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ritonavir", "suffix": ", efavirenz, emtricitabine, lamivudine, methadone, or rilpiv"}, {"to": "18478", "prefix": "ritonavir, ", "from": "18470", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "efavirenz", "suffix": ", emtricitabine, lamivudine, methadone, or rilpivirine.\n    "}, {"to": "18516", "prefix": "ritonavir, efavirenz, emtricitabine, lamivudine, ", "from": "18508", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "methadone", "suffix": ", or rilpivirine.\n                           \n              "}, {"to": "222", "prefix": "             \n                           Increased INR and ", "from": "212", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prothrombin", "suffix": " times have been reported with concomitant use with warfarin"}, {"to": "1976", "prefix": "              There have been reports of increased INR and ", "from": "1966", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prothrombin", "suffix": " time in patients receiving proton pump inhibitors, includin"}, {"to": "2111", "prefix": "eprazole, and warfarin concomitantly. Increases in INR and ", "from": "2101", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prothrombin", "suffix": " time may lead to abnormal bleeding and even death [see Warn"}, {"to": "282", "prefix": "hrombin times have been reported with concomitant use with ", "from": "275", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "warfarin", "suffix": ". Patients need to be monitored "}, {"to": "1387", "prefix": "with other drugs metabolized by the CYP450 system, such as ", "from": "1380", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "warfarin", "suffix": " and theophylline given as single oral doses, diazepam as a "}, {"to": "1872", "prefix": "          \n                     \n                     \n7.2 ", "from": "1865", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Warfarin", "suffix": "\n\n                     \n                        There have b"}, {"to": "2063", "prefix": "ceiving proton pump inhibitors, including rabeprazole, and ", "from": "2056", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "warfarin", "suffix": " concomitantly. Increases in INR and prothrombin time may le"}, {"to": "359", "prefix": ".\n                           ", "from": "349", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " has been shown to inhibit cyclosporine metabolism in  vitro "}, {"to": "1133", "prefix": "ed by CYP450\n                     \n                        ", "from": "1123", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is metabolized by the cytochrome P450 "}, {"to": "1269", "prefix": "enzyme system. Studies in healthy subjects have shown that ", "from": "1259", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " does not have clinically significant interactions with othe"}, {"to": "1594", "prefix": ". Steady state interactions of ", "from": "1584", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and other drugs metabolized by this enzyme system have not "}, {"to": "2049", "prefix": "me in patients receiving proton pump inhibitors, including ", "from": "2039", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", and warfarin concomitantly. Increases in INR and prothromb"}, {"to": "2552", "prefix": "ncubations employing human liver microsomes indicated that ", "from": "2542", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " inhibited cyclosporine metabolism with an IC50 of 62  microm"}, {"to": "2752", "prefix": "althy volunteers following 14  days of dosing with 20  mg of ", "from": "2742", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ". This degree of inhibition is similar to that by omeprazole"}, {"to": "3178", "prefix": "             Due to its effects on gastric acid secretion, ", "from": "3168", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " can reduce the absorption of drugs where gastric pH is an i"}, {"to": "3628", "prefix": "PHEX.   \n                        Concomitant treatment with ", "from": "3618", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " "}, {"to": "3907", "prefix": " be monitored when such drugs are taken concomitantly with ", "from": "3897", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ". Co-administration of rabeprazole and antacids produced no "}, {"to": "3941", "prefix": "taken concomitantly with rabeprazole. Co-administration of ", "from": "3931", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and antacids produced no clinically relevant changes in pla"}, {"to": "4016", "prefix": "antacids produced no clinically relevant changes in plasma ", "from": "4006", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " concentrations.\n                        Concomitant use of "}, {"to": "5060", "prefix": "                   In a clinical study in Japan evaluating ", "from": "5050", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " in adult patients categorized by CYP2C19 genotype "}, {"to": "5275", "prefix": "red to extensive metabolizers. This could be due to higher ", "from": "5265", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " plasma levels in poor metabolizers. Whether or not interact"}, {"to": "5820", "prefix": "                     Combined administration consisting of ", "from": "5810", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", amoxicillin, and clarithromycin resulted in increases in p"}, {"to": "5915", "prefix": "hromycin resulted in increases in plasma concentrations of ", "from": "5905", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and 14-hydroxyclarithromycin [see Clinical Pharmacology "}, {"to": "7426", "prefix": "    \n                        Concomitant administration of ", "from": "7416", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and clopidogrel in healthy subjects had no clinically meani"}, {"to": "460", "prefix": ".\n                           ", "from": "454", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " inhibits gastric acid secretion and may interfere with the "}, {"to": "714", "prefix": ".\n                           ", "from": "708", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " may reduce the plasma levels of atazanavir "}, {"to": "813", "prefix": ".\n                           Methotrexate: ", "from": "807", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " may increase serum level of methotrexate "}, {"to": "3562", "prefix": "f drugs such as digoxin can increase during treatment with ", "from": "3556", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ".   \n                        Concomitant treatment with rabep"}, {"to": "4697", "prefix": "blished in transplant patients receiving PPIs and MMF. Use ", "from": "4691", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " with caution in transplant patients receiving MMF.\n        "}, {"to": "5361", "prefix": "evels in poor metabolizers. Whether or not interactions of ", "from": "5344", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole sodium", "suffix": " with other drugs metabolized by CYP2C19 would be different "}, {"to": "7684", "prefix": "el is necessary when administered with an approved dose of ", "from": "7678", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ".\n                     \n                     \n              "}, {"to": "398", "prefix": "                     Rabeprazole has been shown to inhibit ", "from": "387", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cyclosporine", "suffix": " metabolism in  vitro "}, {"to": "2396", "prefix": "          \n                     \n                     \n7.3 ", "from": "2385", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Cyclosporine", "suffix": "\n\n                     \n                        \n           "}, {"to": "2575", "prefix": "uman liver microsomes indicated that rabeprazole inhibited ", "from": "2564", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cyclosporine", "suffix": " metabolism with an IC50 of 62  micromolar, a concentration t"}, {"to": "623", "prefix": "e.g., ", "from": "612", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": ", iron salts, digoxin, and mycophenolate mofetil"}, {"to": "3391", "prefix": " the intragastric acidity, the absorption of drugs such as ", "from": "3380", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": ", atazanavir, iron salts, erlotinib, and mycophenolate mofet"}, {"to": "3659", "prefix": " and ", "from": "3648", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": " in healthy subjects decreased the bioavailability of ketoco"}, {"to": "3725", "prefix": "azole in healthy subjects decreased the bioavailability of ", "from": "3714", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": " by 30% and increased the AUC and Cmax for digoxin by 19% an"}, {"to": "644", "prefix": "e.g., ketoconazole, iron salts, ", "from": "638", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "digoxin", "suffix": ", and mycophenolate mofetil"}, {"to": "3519", "prefix": " can decrease, while the absorption of drugs such as ", "from": "3513", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "digoxin", "suffix": " can increase during treatment with ACIPHEX.   \n             "}, {"to": "3775", "prefix": " of ketoconazole by 30% and increased the AUC and Cmax for ", "from": "3769", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "digoxin", "suffix": " by 19% and 29%, respectively. Therefore, patients may need "}, {"to": "671", "prefix": "e.g., ketoconazole, iron salts, digoxin, and ", "from": "651", "name": "mycophenolate mofetil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68149", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "mycophenolate mofetil", "suffix": ""}, {"to": "3453", "prefix": "ch as ketoconazole, atazanavir, iron salts, erlotinib, and ", "from": "3433", "name": "mycophenolate mofetil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68149", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "mycophenolate mofetil", "suffix": " "}, {"to": "757", "prefix": "                   ACIPHEX may reduce the plasma levels of ", "from": "748", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " "}, {"to": "3403", "prefix": "ric acidity, the absorption of drugs such as ketoconazole, ", "from": "3394", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": ", iron salts, erlotinib, and mycophenolate mofetil "}, {"to": "4086", "prefix": "concentrations.\n                        Concomitant use of ", "from": "4077", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " and PPIs is not recommended. Co-administration of atazanavi"}, {"to": "4147", "prefix": "azanavir and PPIs is not recommended. Co-administration of ", "from": "4138", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " with PPIs is expected to substantially decrease atazanavir "}, {"to": "4206", "prefix": "atazanavir with PPIs is expected to substantially decrease ", "from": "4197", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " plasma concentrations and thereby reduce its therapeutic ef"}, {"to": "804", "prefix": ".\n                           ", "from": "793", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Methotrexate", "suffix": ": ACIPHEX may increase serum level of methotrexate "}, {"to": "854", "prefix": "         Methotrexate: ACIPHEX may increase serum level of ", "from": "843", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " "}, {"to": "6652", "prefix": "           \n                     \n                     7.7 ", "from": "6641", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Methotrexate", "suffix": "\n                     \n                        Case reports,"}, {"to": "6850", "prefix": "alyses suggest that concomitant administration of PPIs and ", "from": "6839", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " "}, {"to": "6892", "prefix": "primarily at high dose; see ", "from": "6881", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " prescribing information"}, {"to": "6970", "prefix": " may elevate and prolong serum levels of ", "from": "6959", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " and"}, {"to": "7073", "prefix": "thotrexate. However, no formal drug interaction studies of ", "from": "7062", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " with PPIs have been conducted [see Warnings and Precautions"}, {"to": "1404", "prefix": "ugs metabolized by the CYP450 system, such as warfarin and ", "from": "1393", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "theophylline", "suffix": " given as single oral doses, diazepam as a single intravenou"}, {"to": "1441", "prefix": "h as warfarin and theophylline given as single oral doses, ", "from": "1434", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "diazepam", "suffix": " as a single intravenous dose, and phenytoin given as a sing"}, {"to": "1485", "prefix": "gle oral doses, diazepam as a single intravenous dose, and ", "from": "1477", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "phenytoin", "suffix": " given as a single intravenous dose "}, {"to": "2812", "prefix": "beprazole. This degree of inhibition is similar to that by ", "from": "2803", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "omeprazole", "suffix": " at equivalent concentrations.\n                     \n       "}, {"to": "3426", "prefix": "ion of drugs such as ketoconazole, atazanavir, iron salts, ", "from": "3418", "name": "erlotinib", "fullId": "http://purl.bioontology.org/ontology/MESH/C400278", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "erlotinib", "suffix": ", and mycophenolate mofetil "}, {"to": "5723", "prefix": "   \n                     \n7.6 Combined Administration with ", "from": "5710", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clarithromycin", "suffix": "\n\n                     \n                        Combined adm"}, {"to": "5853", "prefix": "administration consisting of rabeprazole, amoxicillin, and ", "from": "5840", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " resulted in increases in plasma concentrations of rabeprazo"}, {"to": "6049", "prefix": "].\n                        Concomitant administration of ", "from": "6036", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " with other drugs can lead to serious adverse reactions due "}, {"to": "6205", "prefix": "ee Warnings and Precautions in prescribing information for ", "from": "6192", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": "]. Because of these drug interactions, clarithromycin is con"}, {"to": "6258", "prefix": "n for clarithromycin]. Because of these drug interactions, ", "from": "6245", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " is contraindicated for co-administration with certain drugs"}, {"to": "6387", "prefix": "rugs [see Contraindications in prescribing information for ", "from": "6374", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": "] [see Drug Interactions in prescribing information for amox"}, {"to": "5833", "prefix": "        Combined administration consisting of rabeprazole, ", "from": "5823", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ", and clarithromycin resulted in increases in plasma concent"}, {"to": "6454", "prefix": "cin] [see Drug Interactions in prescribing information for ", "from": "6444", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": "].\n                     \n                     \n             "}, {"to": "7337", "prefix": "          \n                     \n                     \n7.8 ", "from": "7327", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clopidogrel", "suffix": "\n\n                     \n                        Concomitant "}, {"to": "7442", "prefix": "             Concomitant administration of rabeprazole and ", "from": "7432", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " in healthy subjects had no clinically meaningful effect on "}, {"to": "7550", "prefix": " meaningful effect on exposure to the active metabolite of ", "from": "7540", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " [see Clinical Pharmacology "}, {"to": "7620", "prefix": "]. No dose adjustment of ", "from": "7610", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " is necessary when administered with an approved dose of ACI"}, {"to": "225", "prefix": "         \n                           Coadministration with ", "from": "216", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "amiodarone", "suffix": " may result in serious symptomatic bradycardia. Use of HARVO"}, {"to": "303", "prefix": "lt in serious symptomatic bradycardia. Use of HARVONI with ", "from": "294", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "amiodarone", "suffix": " is not recommended "}, {"to": "395", "prefix": "e.g., ", "from": "388", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rifampin", "suffix": ", St. John's wort"}, {"to": "1744", "prefix": "e.g., ", "from": "1737", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rifampin", "suffix": " or St. John's wort"}, {"to": "453", "prefix": ": May alter concentrations of ", "from": "444", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir. Use of HARVONI with P-gp inducers is not re"}, {"to": "965", "prefix": "              \n                        As HARVONI contains ", "from": "956", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir, any interactions that have been identified "}, {"to": "1408", "prefix": "poses of pharmacokinetic analyses.\n                        ", "from": "1399", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of the drug transporters P-gp and breast ca"}, {"to": "1625", "prefix": "substrates for these transporters.\n                        ", "from": "1616", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " and sofosbuvir are substrates of drug transporters P-gp and"}, {"to": "1788", "prefix": " may decrease ", "from": "1779", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir plasma concentrations, leading to reduced th"}, {"to": "2485", "prefix": "", "from": "2476", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir"}, {"to": "3071", "prefix": "", "from": "3062", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir"}, {"to": "468", "prefix": ": May alter concentrations of ledipasvir and ", "from": "459", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". Use of HARVONI with P-gp inducers is not recommended "}, {"to": "980", "prefix": "                        As HARVONI contains ledipasvir and ", "from": "971", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", any interactions that have been identified with these agen"}, {"to": "1152", "prefix": "                     After oral administration of HARVONI, ", "from": "1143", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " is rapidly absorbed and subject to extensive first-pass hep"}, {"to": "1278", "prefix": "hepatic extraction. In clinical pharmacology studies, both ", "from": "1269", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and the inactive metabolite GS-331007 were monitored for pu"}, {"to": "1640", "prefix": "these transporters.\n                        Ledipasvir and ", "from": "1631", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " are substrates of drug transporters P-gp and BCRP while GS-"}, {"to": "1803", "prefix": " may decrease ledipasvir and ", "from": "1794", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " plasma concentrations, leading to reduced therapeutic effec"}, {"to": "2500", "prefix": "ledipasvir and ", "from": "2491", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ""}, {"to": "3085", "prefix": "ledipasvir or ", "from": "3076", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ""}, {"to": "3288", "prefix": "]: ", "from": "3281", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "abacavir", "suffix": ", atazanavir"}, {"to": "3300", "prefix": "]: abacavir, ", "from": "3291", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "atazanavir", "suffix": ""}, {"to": "3310", "prefix": "", "from": "3302", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ritonavir", "suffix": ", cyclosporine, darunavir"}, {"to": "3345", "prefix": "", "from": "3337", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ritonavir", "suffix": ", efavirenz, emtricitabine, lamivudine, methadone, oral cont"}, {"to": "3324", "prefix": "ritonavir, ", "from": "3313", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "cyclosporine", "suffix": ", darunavir"}, {"to": "3335", "prefix": "ritonavir, cyclosporine, ", "from": "3327", "name": "darunavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C482292", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "darunavir", "suffix": ""}, {"to": "3356", "prefix": "ritonavir, ", "from": "3348", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "efavirenz", "suffix": ", emtricitabine, lamivudine, methadone, oral contraceptives,"}, {"to": "3371", "prefix": "ritonavir, efavirenz, ", "from": "3359", "name": "emtricitabine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/276237", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "emtricitabine", "suffix": ", lamivudine, methadone, oral contraceptives, pravastatin, r"}, {"to": "3383", "prefix": "ritonavir, efavirenz, emtricitabine, ", "from": "3374", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "lamivudine", "suffix": ", methadone, oral contraceptives, pravastatin, raltegravir, "}, {"to": "3394", "prefix": "ritonavir, efavirenz, emtricitabine, lamivudine, ", "from": "3386", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "methadone", "suffix": ", oral contraceptives, pravastatin, raltegravir, rilpivirine"}, {"to": "3428", "prefix": "emtricitabine, lamivudine, methadone, oral contraceptives, ", "from": "3418", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "pravastatin", "suffix": ", raltegravir, rilpivirine, tacrolimus, tenofovir disoproxil"}, {"to": "3441", "prefix": ", lamivudine, methadone, oral contraceptives, pravastatin, ", "from": "3431", "name": "raltegravir", "fullId": "http://purl.bioontology.org/ontology/MESH/C507898", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "raltegravir", "suffix": ", rilpivirine, tacrolimus, tenofovir disoproxil fumarate, or"}, {"to": "3454", "prefix": " methadone, oral contraceptives, pravastatin, raltegravir, ", "from": "3444", "name": "Rilpivirine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102270", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rilpivirine", "suffix": ", tacrolimus, tenofovir disoproxil fumarate, or verapamil. S"}, {"to": "3466", "prefix": "ral contraceptives, pravastatin, raltegravir, rilpivirine, ", "from": "3457", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "tacrolimus", "suffix": ", tenofovir disoproxil fumarate, or verapamil. See Table 3 f"}, {"to": "3497", "prefix": "ptives, pravastatin, raltegravir, rilpivirine, tacrolimus, ", "from": "3469", "name": "tenofovir disoproxil", "fullId": "http://purl.bioontology.org/ontology/MESH/C418563", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "tenofovir disoproxil fumarate", "suffix": ", or verapamil. See Table 3 for use of HARVONI with certain "}, {"to": "3511", "prefix": "rilpivirine, tacrolimus, tenofovir disoproxil fumarate, or ", "from": "3503", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "verapamil", "suffix": ". See Table 3 for use of HARVONI with certain HIV antiretrov"}, {"to": "205", "prefix": "      \n                        \n                           ", "from": "195", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Apomorphine", "suffix": " "}, {"to": "1264", "prefix": "           \n                     \n                     7.2 ", "from": "1254", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Apomorphine", "suffix": "\n\n                     \n                         Based on re"}, {"to": "1396", "prefix": "rts of profound hypotension and loss of consciousness when ", "from": "1386", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "apomorphine", "suffix": " was administered with ondansetron, concomitant use of apomo"}, {"to": "1462", "prefix": "hine was administered with ondansetron, concomitant use of ", "from": "1452", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "apomorphine", "suffix": " with ondansetron is contraindicated [see Contraindications "}, {"to": "288", "prefix": "ypotension and loss of consciousness.\nConcomitant use with ", "from": "278", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is contraindicated. "}, {"to": "602", "prefix": "50 Enzymes\n\n                     \n                         ", "from": "592", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " does not appear to induce or inhibit the cytochrome P-450 d"}, {"to": "726", "prefix": "-450 drug-metabolizing enzyme system of the liver. Because ", "from": "716", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is metabolized by hepatic cytochrome P-450 drug-metabolizin"}, {"to": "927", "prefix": "ymes may change the clearance and, hence, the half-life of ", "from": "917", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " [see Clinical Pharmacology "}, {"to": "1430", "prefix": "ss of consciousness when apomorphine was administered with ", "from": "1420", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ", concomitant use of apomorphine with ondansetron is contrai"}, {"to": "1479", "prefix": "ered with ondansetron, concomitant use of apomorphine with ", "from": "1469", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is contraindicated [see Contraindications "}, {"to": "1950", "prefix": ", the clearance of ", "from": "1940", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " was significantly increased and ondansetron blood concentra"}, {"to": "1994", "prefix": "e clearance of ondansetron was significantly increased and ", "from": "1984", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " blood concentrations were decreased. However, on the basis "}, {"to": "2109", "prefix": ", on the basis of available data, no dosage adjustment for ", "from": "2099", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is recommended for patients on these drugs [see Clinical Ph"}, {"to": "2513", "prefix": "e are no data on pharmacokinetic drug interactions between ", "from": "2503", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " and tramadol, data from two small studies indicate that con"}, {"to": "2600", "prefix": "ta from two small studies indicate that concomitant use of ", "from": "2590", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " may result in reduced analgesic activity of tramadol. Patie"}, {"to": "2690", "prefix": "ed analgesic activity of tramadol. Patients on concomitant ", "from": "2680", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " self administered tramadol more frequently in these studies"}, {"to": "3810", "prefix": "oside, and cisplatin do not affect the pharmacokinetics of ", "from": "3800", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ".\n\n                         In a crossover study in 76 pedia"}, {"to": "3908", "prefix": "In a crossover study in 76 pediatric patients, intravenous ", "from": "3898", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " did not increase blood levels of high-dose methotrexate.\n\n "}, {"to": "4243", "prefix": "         \n                         The coadministration of ", "from": "4233", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " had no effect on the pharmacokinetics and pharmacodynamics "}, {"to": "4586", "prefix": "Atracurium\n\n                     \n                         ", "from": "4576", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " does not alter the respiratory depressant effects produced "}, {"to": "1745", "prefix": "           \n                     \n                     7.3 ", "from": "1737", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Phenytoin", "suffix": ", Carbamazepine, and Rifampin\n\n                     \n       "}, {"to": "1890", "prefix": "i.e., ", "from": "1882", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "phenytoin", "suffix": ", carbamazepine, and rifampin"}, {"to": "1760", "prefix": "\n                     \n                     7.3 Phenytoin, ", "from": "1748", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Carbamazepine", "suffix": ", and Rifampin\n\n                     \n                      "}, {"to": "1905", "prefix": "i.e., phenytoin, ", "from": "1893", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "carbamazepine", "suffix": ", and rifampin"}, {"to": "1774", "prefix": "   \n                     7.3 Phenytoin, Carbamazepine, and ", "from": "1767", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Rifampin", "suffix": "\n\n                     \n                         In patients"}, {"to": "1919", "prefix": "i.e., phenytoin, carbamazepine, and ", "from": "1912", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "rifampin", "suffix": ""}, {"to": "2381", "prefix": "           \n                     \n                     7.4 ", "from": "2374", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Tramadol", "suffix": "\n\n                     \n                         Although th"}, {"to": "2526", "prefix": " pharmacokinetic drug interactions between ondansetron and ", "from": "2519", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": ", data from two small studies indicate that concomitant use "}, {"to": "2653", "prefix": "of ondansetron may result in reduced analgesic activity of ", "from": "2646", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": ". Patients on concomitant ondansetron self administered tram"}, {"to": "2717", "prefix": "dol. Patients on concomitant ondansetron self administered ", "from": "2710", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": " more frequently in these studies, leading to an increased c"}, {"to": "2846", "prefix": " of ", "from": "2839", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": ".\n\n                     \n                     \n             "}, {"to": "3108", "prefix": "rgic Drugs\n\n                     \n                         ", "from": "3100", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Serotonin", "suffix": " syndrome "}, {"to": "3383", "prefix": " and ", "from": "3375", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "serotonin", "suffix": " and noradrenaline reuptake inhibitors "}, {"to": "3401", "prefix": " and serotonin and ", "from": "3389", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "noradrenaline", "suffix": " reuptake inhibitors "}, {"to": "3734", "prefix": "\n                     \n                         In humans, ", "from": "3725", "name": "Carmustine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2105", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "carmustine", "suffix": ", etoposide, and cisplatin do not affect the pharmacokinetic"}, {"to": "3745", "prefix": "          \n                         In humans, carmustine, ", "from": "3737", "name": "Etoposide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4179", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "etoposide", "suffix": ", and cisplatin do not affect the pharmacokinetics of ondans"}, {"to": "3760", "prefix": "                     In humans, carmustine, etoposide, and ", "from": "3752", "name": "Cisplatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2555", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "cisplatin", "suffix": " do not affect the pharmacokinetics of ondansetron.\n\n       "}, {"to": "3964", "prefix": "ous ondansetron did not increase blood levels of high-dose ", "from": "3953", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "methotrexate", "suffix": ".\n\n                     \n                     \n             "}, {"to": "4159", "prefix": "           \n                     \n                     7.7 ", "from": "4151", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Temazepam", "suffix": "\n\n                     \n                         The coadmin"}, {"to": "4315", "prefix": " no effect on the pharmacokinetics and pharmacodynamics of ", "from": "4307", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "temazepam", "suffix": ".\n\n                     \n                     \n             "}, {"to": "4511", "prefix": "           \n                     \n                     7.8 ", "from": "4502", "name": "Alfentanil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015760", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Alfentanil", "suffix": " and Atracurium\n\n                     \n                     "}, {"to": "4659", "prefix": "s not alter the respiratory depressant effects produced by ", "from": "4650", "name": "Alfentanil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015760", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "alfentanil", "suffix": " or the degree of neuromuscular blockade produced by atracur"}, {"to": "4526", "prefix": "                  \n                     7.8 Alfentanil and ", "from": "4517", "name": "Atracurium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1218", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Atracurium", "suffix": "\n\n                     \n                         Ondansetron"}, {"to": "4722", "prefix": "ntanil or the degree of neuromuscular blockade produced by ", "from": "4713", "name": "Atracurium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1218", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "atracurium", "suffix": ". Interactions with general or local anesthetics have not be"}, {"to": "134", "prefix": "IONS\n               \n                  \n\n                  ", "from": "123", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is extensively metabolized in the liver by CYP2C19 and CYP3"}, {"to": "300", "prefix": "              In vitro and in vivo studies have shown that ", "from": "289", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3"}, {"to": "516", "prefix": "ould be expected. Drug interaction studies have shown that ", "from": "505", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " does not have any clinically significant interactions with "}, {"to": "770", "prefix": "e been received among patients on concomitant warfarin and ", "from": "759", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " therapy. Increases in INR and prothrombin time may lead to "}, {"to": "1039", "prefix": "reases in INR and prothrombin time.\n\n                     \n", "from": "1028", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may potentially interfere with CYP2C19, the major esomepraz"}, {"to": "1102", "prefix": "eprazole may potentially interfere with CYP2C19, the major ", "from": "1091", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " metabolizing enzyme. Coadministration of esomeprazole 30 mg"}, {"to": "1156", "prefix": "ajor esomeprazole metabolizing enzyme. Coadministration of ", "from": "1145", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% "}, {"to": "1675", "prefix": "s active metabolite in part by CYP2C19. Concomitant use of ", "from": "1664", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " 40 mg results in reduced plasma concentrations of the activ"}, {"to": "1858", "prefix": "n platelet inhibition. Avoid concomitant administration of ", "from": "1840", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " with clopidogrel. When using esomeprazole sodium, consider "}, {"to": "1907", "prefix": "ration of esomeprazole sodium with clopidogrel. When using ", "from": "1889", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": ", consider use of alternative anti-platelet [see Pharmacokin"}, {"to": "2452", "prefix": "and 69%, respectively. Coadministration of cilostazol with ", "from": "2441", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is expected to increase concentrations of cilostazol and it"}, {"to": "2723", "prefix": "ered.\n\n                     \nConcomitant administration of ", "from": "2712", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and a combined inhibitor of CYP2C19 and CYP3A4, such as vor"}, {"to": "2846", "prefix": "h as voriconazole, may result in more than doubling of the ", "from": "2835", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " exposure. Dose adjustment of esomeprazole is not normally r"}, {"to": "2888", "prefix": " doubling of the esomeprazole exposure. Dose adjustment of ", "from": "2877", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is not normally required for the recommended doses. However"}, {"to": "3143", "prefix": " may lead to decreased ", "from": "3132", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " serum levels. Omeprazole, of which esomeprazole is an enant"}, {"to": "3191", "prefix": " decreased esomeprazole serum levels. Omeprazole, of which ", "from": "3180", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is an enantiomer, has been reported to interact with St. Jo"}, {"to": "3699", "prefix": "s Wort or rifampin with ", "from": "3681", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": ". \n  Coadministration of oral contraceptives, diazepam, pheny"}, {"to": "3844", "prefix": "dine did not seem to change the pharmacokinetic profile of ", "from": "3833", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n\n                     \nConcomitant use of atazanavir and p"}, {"to": "5715", "prefix": "         \nStudies evaluating concomitant administration of ", "from": "5704", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and either naproxen "}, {"to": "5891", "prefix": "ically relevant changes in the pharmacokinetic profiles of ", "from": "5880", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " or these NSAIDs.\n\n                     \nEsomeprazole inhibi"}, {"to": "5944", "prefix": "es of esomeprazole or these NSAIDs.\n\n                     \n", "from": "5933", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " inhibits gastric acid secretion. Therefore, esomeprazole ma"}, {"to": "6001", "prefix": " \nEsomeprazole inhibits gastric acid secretion. Therefore, ", "from": "5990", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " may interfere with the absorption of drugs where gastric pH"}, {"to": "6363", "prefix": "f drugs such as digoxin can increase during treatment with ", "from": "6352", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ". Concomitant treatment with omeprazole "}, {"to": "6532", "prefix": ". ", "from": "6521", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is an enantiomer of omeprazole. Coadministration of digoxin"}, {"to": "6610", "prefix": "enantiomer of omeprazole. Coadministration of digoxin with ", "from": "6599", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is expected to increase the systemic exposure of digoxin. T"}, {"to": "6767", "prefix": "d to be monitored when digoxin is taken concomitantly with ", "from": "6756", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n               \n               \n               \n          "}, {"to": "6922", "prefix": "      \n                        \n                           ", "from": "6911", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " inhibits gastric acid secretion and may interfere with the "}, {"to": "7157", "prefix": ". Patients treated with ", "from": "7146", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and digoxin may need to be monitored for digoxin toxicity. "}, {"to": "7431", "prefix": "\n                           ", "from": "7420", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may reduce the plasma levels of atazanavir, nelfinavir, and"}, {"to": "7680", "prefix": "h as voriconazole, may result in more than doubling of the ", "from": "7669", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " exposure. "}, {"to": "7873", "prefix": "\n                           Clopidogrel: ", "from": "7862", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " decreases exposure to the active metabolite of clopidogrel."}, {"to": "7989", "prefix": "\n                           Tacrolimus: ", "from": "7978", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may increase serum levels of tacrolimus "}, {"to": "8089", "prefix": "\n                           Methotrexate: ", "from": "8078", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may increase serum levels of methotrexate   "}, {"to": "9007", "prefix": "    \n                        Concomitant administration of ", "from": "8996", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and tacrolimus may increase the serum levels of tacrolimus."}, {"to": "585", "prefix": "does not have any clinically significant interactions with ", "from": "577", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "phenytoin", "suffix": ", warfarin, quinidine, clarithromycin or amoxicillin. Postma"}, {"to": "3763", "prefix": "dium. \n  Coadministration of oral contraceptives, diazepam, ", "from": "3755", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "phenytoin", "suffix": ", or quinidine did not seem to change the pharmacokinetic pr"}, {"to": "595", "prefix": "ve any clinically significant interactions with phenytoin, ", "from": "588", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": ", quinidine, clarithromycin or amoxicillin. Postmarketing re"}, {"to": "753", "prefix": " measures have been received among patients on concomitant ", "from": "746", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": " and esomeprazole therapy. Increases in INR and prothrombin "}, {"to": "921", "prefix": "en death. Patients treated with proton pump inhibitors and ", "from": "914", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": " concomitantly may need to be monitored for increases in INR"}, {"to": "7305", "prefix": "          Patients treated with proton pump inhibitors and ", "from": "7298", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": " concomitantly may need to be monitored for increases in INR"}, {"to": "606", "prefix": "nically significant interactions with phenytoin, warfarin, ", "from": "598", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "quinidine", "suffix": ", clarithromycin or amoxicillin. Postmarketing reports of ch"}, {"to": "3777", "prefix": "nistration of oral contraceptives, diazepam, phenytoin, or ", "from": "3769", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "quinidine", "suffix": " did not seem to change the pharmacokinetic profile of esome"}, {"to": "622", "prefix": "nificant interactions with phenytoin, warfarin, quinidine, ", "from": "609", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clarithromycin", "suffix": " or amoxicillin. Postmarketing reports of changes in prothro"}, {"to": "637", "prefix": "ons with phenytoin, warfarin, quinidine, clarithromycin or ", "from": "627", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "amoxicillin", "suffix": ". Postmarketing reports of changes in prothrombin measures h"}, {"to": "686", "prefix": "omycin or amoxicillin. Postmarketing reports of changes in ", "from": "676", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " measures have been received among patients on concomitant w"}, {"to": "812", "prefix": "nt warfarin and esomeprazole therapy. Increases in INR and ", "from": "802", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " time may lead to abnormal bleeding and even death. Patients"}, {"to": "997", "prefix": "mitantly may need to be monitored for increases in INR and ", "from": "987", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " time.\n\n                     \nEsomeprazole may potentially i"}, {"to": "7381", "prefix": "mitantly may need to be monitored for increases in INR and ", "from": "7371", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " time. "}, {"to": "1175", "prefix": "olizing enzyme. Coadministration of esomeprazole 30 mg and ", "from": "1168", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": ", a CYP2C19 substrate, resulted in a 45% decrease in clearan"}, {"to": "1249", "prefix": "2C19 substrate, resulted in a 45% decrease in clearance of ", "from": "1242", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": ". Increased plasma levels of diazepam were observed 12 hours"}, {"to": "1286", "prefix": "rease in clearance of diazepam. Increased plasma levels of ", "from": "1279", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": " were observed 12 hours after dosing and onwards.  However, a"}, {"to": "1388", "prefix": "g and onwards.  However, at that time, the plasma levels of ", "from": "1381", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": " were below the therapeutic interval, and thus this interact"}, {"to": "3752", "prefix": "prazole sodium. \n  Coadministration of oral contraceptives, ", "from": "3745", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": ", phenytoin, or quinidine did not seem to change the pharmac"}, {"to": "1549", "prefix": "al relevance.\n\n                     \n\n                     ", "from": "1539", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": "\n                     \nClopidogrel is metabolized to its act"}, {"to": "1583", "prefix": "  \n\n                     Clopidogrel\n                     \n", "from": "1573", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": " is metabolized to its active metabolite in part by CYP2C19."}, {"to": "1762", "prefix": " reduced plasma concentrations of the active metabolite of ", "from": "1752", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " and a reduction in platelet inhibition. Avoid concomitant a"}, {"to": "1875", "prefix": "oid concomitant administration of esomeprazole sodium with ", "from": "1865", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": ". When using esomeprazole sodium, consider use of alternativ"}, {"to": "7859", "prefix": "\n                           ", "from": "7849", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": ": Esomeprazole decreases exposure to the active metabolite o"}, {"to": "7932", "prefix": "someprazole decreases exposure to the active metabolite of ", "from": "7922", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": ". "}, {"to": "2037", "prefix": "\n                     ].\n\n                     \n", "from": "2028", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": " acts as an inhibitor of CYP2C19. Omeprazole, given in doses"}, {"to": "2081", "prefix": "              \nOmeprazole acts as an inhibitor of CYP2C19. ", "from": "2072", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": ", given in doses of 40 mg daily for one week to 20 healthy s"}, {"to": "3168", "prefix": " may lead to decreased esomeprazole serum levels. ", "from": "3159", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": ", of which esomeprazole is an enantiomer, has been reported "}, {"to": "3448", "prefix": " significantly decreased the systemic exposure of ", "from": "3439", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " in CYP2C19 poor metabolizers "}, {"to": "4152", "prefix": "reby reduce its therapeutic effect.\n\n                     \n", "from": "4143", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": " has been reported to interact with some antiretroviral drug"}, {"to": "4344", "prefix": "ractions are not always known. Increased gastric pH during ", "from": "4335", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " treatment may change the absorption of the antiretroviral d"}, {"to": "4607", "prefix": "d serum levels have been reported when given together with ", "from": "4598", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": ". Following multiple doses of nelfinavir "}, {"to": "4685", "prefix": " and ", "from": "4676", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " "}, {"to": "4885", "prefix": " and ", "from": "4876", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " "}, {"to": "5023", "prefix": "x by 96%, and Cmin by 95%. Concomitant administration with ", "from": "5014", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " and drugs such as atazanavir and nelfinavir is therefore no"}, {"to": "5365", "prefix": " twice daily for 15 days with ", "from": "5356", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " 40 mg daily coadministered days 11 to 15. Dose reduction of"}, {"to": "5629", "prefix": " unchanged serum levels have been reported when given with ", "from": "5620", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": ".\n\n                     \nStudies evaluating concomitant admi"}, {"to": "6402", "prefix": "ng treatment with esomeprazole. Concomitant treatment with ", "from": "6393", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " "}, {"to": "6563", "prefix": ". Esomeprazole is an enantiomer of ", "from": "6554", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": ". Coadministration of digoxin with esomeprazole is expected "}, {"to": "2206", "prefix": "hy subjects in cross-over study, increased Cmax and AUC of ", "from": "2197", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " by 18% and 26%, respectively. Cmax and AUC of one of its ac"}, {"to": "2306", "prefix": "Cmax and AUC of one of its active metabolites, 3,4-dihydro-", "from": "2297", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": ", which has 4 to 7 times the activity of cilostazol, were in"}, {"to": "2357", "prefix": "dihydro-cilostazol, which has 4 to 7 times the activity of ", "from": "2348", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": ", were increased by 29% and 69%, respectively. Coadministrat"}, {"to": "2434", "prefix": "ncreased by 29% and 69%, respectively. Coadministration of ", "from": "2425", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " with esomeprazole is expected to increase concentrations of"}, {"to": "2505", "prefix": "ith esomeprazole is expected to increase concentrations of ", "from": "2496", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " and its above mentioned active metabolite. Therefore, a dos"}, {"to": "2590", "prefix": "entioned active metabolite. Therefore, a dose reduction of ", "from": "2581", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " from 100 mg twice daily to 50 mg twice daily should be cons"}, {"to": "7766", "prefix": "                         May increase systemic exposure of ", "from": "7757", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " and an active metabolite. Consider dose reduction "}, {"to": "2792", "prefix": "le and a combined inhibitor of CYP2C19 and CYP3A4, such as ", "from": "2781", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "voriconazole", "suffix": ", may result in more than doubling of the esomeprazole expos"}, {"to": "7626", "prefix": "t with a combined inhibitor of CYP2C19 and CYP3A4, such as ", "from": "7615", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "voriconazole", "suffix": ", may result in more than doubling of the esomeprazole expos"}, {"to": "3107", "prefix": "such as ", "from": "3100", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "rifampin", "suffix": ""}, {"to": "3674", "prefix": "s Wort or ", "from": "3667", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "rifampin", "suffix": " with esomeprazole sodium. \n  Coadministration of oral contra"}, {"to": "3898", "prefix": "of esomeprazole.\n\n                     \nConcomitant use of ", "from": "3889", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " and proton pump inhibitors is not recommended. Coadministra"}, {"to": "3976", "prefix": "on pump inhibitors is not recommended. Coadministration of ", "from": "3967", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " with proton pump inhibitors is expected to substantially de"}, {"to": "4053", "prefix": "oton pump inhibitors is expected to substantially decrease ", "from": "4044", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " plasma concentrations and thereby reduce its therapeutic ef"}, {"to": "4513", "prefix": "ms are via CYP2C19. For some antiretroviral drugs, such as ", "from": "4504", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " and nelfinavir, decreased serum levels have been reported w"}, {"to": "4855", "prefix": "tively, for nelfinavir and M8. Following multiple doses of ", "from": "4846", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " "}, {"to": "4922", "prefix": "40 mg daily, 2 hr before ", "from": "4913", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": ""}, {"to": "5052", "prefix": "ncomitant administration with omeprazole and drugs such as ", "from": "5043", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " and nelfinavir is therefore not recommended. For other anti"}, {"to": "6228", "prefix": "ric acidity, the absorption of drugs such as ketoconazole, ", "from": "6219", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": ", iron salts, and erlotinib can decrease, while the absorpti"}, {"to": "7474", "prefix": "              Esomeprazole may reduce the plasma levels of ", "from": "7465", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": ", nelfinavir, and saquinavir. "}, {"to": "4528", "prefix": "C19. For some antiretroviral drugs, such as atazanavir and ", "from": "4519", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": ", decreased serum levels have been reported when given toget"}, {"to": "4647", "prefix": "iven together with omeprazole. Following multiple doses of ", "from": "4638", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": " "}, {"to": "4808", "prefix": " by 37% and 89% and Cmin by 39% and 75%, respectively, for ", "from": "4799", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": " and M8. Following multiple doses of atazanavir "}, {"to": "5067", "prefix": "istration with omeprazole and drugs such as atazanavir and ", "from": "5058", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": " is therefore not recommended. For other antiretroviral drug"}, {"to": "7486", "prefix": "  Esomeprazole may reduce the plasma levels of atazanavir, ", "from": "7477", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": ", and saquinavir. "}, {"to": "5148", "prefix": "e not recommended. For other antiretroviral drugs, such as ", "from": "5139", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": ", elevated serum levels have been reported with an increase "}, {"to": "5297", "prefix": "ax by 75% and in Cmin by 106% following multiple dosing of ", "from": "5288", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": ""}, {"to": "5436", "prefix": "0 mg daily coadministered days 11 to 15. Dose reduction of ", "from": "5427", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": " should be considered from the safety perspective for indivi"}, {"to": "7502", "prefix": "ay reduce the plasma levels of atazanavir, nelfinavir, and ", "from": "7493", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": ". "}, {"to": "5307", "prefix": "", "from": "5299", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "ritonavir", "suffix": " "}, {"to": "5735", "prefix": "ting concomitant administration of esomeprazole and either ", "from": "5728", "name": "Naproxen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "naproxen", "suffix": " "}, {"to": "5770", "prefix": " or ", "from": "5762", "name": "rofecoxib", "fullId": "http://purl.bioontology.org/ontology/RXNORM/232158", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "rofecoxib", "suffix": " "}, {"to": "6216", "prefix": " the intragastric acidity, the absorption of drugs such as ", "from": "6205", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "ketoconazole", "suffix": ", atazanavir, iron salts, and erlotinib can decrease, while "}, {"to": "7084", "prefix": "e.g. ", "from": "7073", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "ketoconazole", "suffix": ", iron salts, erlotinib,  and digoxin"}, {"to": "6255", "prefix": "of drugs such as ketoconazole, atazanavir, iron salts, and ", "from": "6247", "name": "erlotinib", "fullId": "http://purl.bioontology.org/ontology/MESH/C400278", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "erlotinib", "suffix": " can decrease, while the absorption of drugs such as digoxin"}, {"to": "7107", "prefix": "e.g. ketoconazole, iron salts, ", "from": "7099", "name": "erlotinib", "fullId": "http://purl.bioontology.org/ontology/MESH/C400278", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "erlotinib", "suffix": ",  and digoxin"}, {"to": "6315", "prefix": "otinib can decrease, while the absorption of drugs such as ", "from": "6309", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " can increase during treatment with esomeprazole. Concomitan"}, {"to": "6428", "prefix": " and ", "from": "6422", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " in healthy subjects increased the bioavailability of digoxi"}, {"to": "6489", "prefix": "goxin in healthy subjects increased the bioavailability of ", "from": "6483", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " by 10% "}, {"to": "6592", "prefix": "razole is an enantiomer of omeprazole. Coadministration of ", "from": "6586", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " with esomeprazole is expected to increase the systemic expo"}, {"to": "6667", "prefix": "meprazole is expected to increase the systemic exposure of ", "from": "6661", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": ". Therefore, patients may need to be monitored when digoxin "}, {"to": "6726", "prefix": "digoxin. Therefore, patients may need to be monitored when ", "from": "6720", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " is taken concomitantly with esomeprazole.\n               \n "}, {"to": "7120", "prefix": "e.g. ketoconazole, iron salts, erlotinib,  and ", "from": "7114", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": ""}, {"to": "7169", "prefix": ". Patients treated with esomeprazole and ", "from": "7163", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " may need to be monitored for digoxin toxicity. "}, {"to": "7206", "prefix": "with esomeprazole and digoxin may need to be monitored for ", "from": "7200", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " toxicity. "}, {"to": "7975", "prefix": "\n                           ", "from": "7966", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Tacrolimus", "suffix": ": Esomeprazole may increase serum levels of tacrolimus "}, {"to": "8029", "prefix": "     Tacrolimus: Esomeprazole may increase serum levels of ", "from": "8020", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "tacrolimus", "suffix": " "}, {"to": "8917", "prefix": "", "from": "8908", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Tacrolimus", "suffix": " \n                     \n                        Concomitant "}, {"to": "9022", "prefix": "            Concomitant administration of esomeprazole and ", "from": "9013", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "tacrolimus", "suffix": " may increase the serum levels of tacrolimus.\n              "}, {"to": "9066", "prefix": "omeprazole and tacrolimus may increase the serum levels of ", "from": "9057", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "tacrolimus", "suffix": ".\n                     \n                     \n              "}, {"to": "8075", "prefix": "\n                           ", "from": "8064", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Methotrexate", "suffix": ": Esomeprazole may increase serum levels of methotrexate   "}, {"to": "8131", "prefix": "   Methotrexate: Esomeprazole may increase serum levels of ", "from": "8120", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": "   "}, {"to": "9263", "prefix": "", "from": "9252", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Methotrexate", "suffix": "\n                     \n                        Case reports,"}, {"to": "9461", "prefix": "alyses suggest that concomitant administration of PPIs and ", "from": "9450", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " "}, {"to": "9503", "prefix": "primarily at high dose; see ", "from": "9492", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " prescribing information"}, {"to": "9581", "prefix": " may elevate and prolong serum levels of ", "from": "9570", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " and"}, {"to": "9684", "prefix": "thotrexate. However, no formal drug interaction studies of ", "from": "9673", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " with PPIs have been conducted [see Warnings and Precautions"}, {"to": "275", "prefix": "m of Action\n\n                     \n                        ", "from": "265", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " belongs to a class of antisecretory compounds "}, {"to": "682", "prefix": " pump within the parietal cell, ", "from": "672", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " has been characterized as a gastric proton-pump inhibitor. "}, {"to": "753", "prefix": "has been characterized as a gastric proton-pump inhibitor. ", "from": "743", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " blocks the final step of gastric acid secretion.\n          "}, {"to": "865", "prefix": "retion.\n                        In gastric parietal cells, ", "from": "855", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is protonated, accumulates, and is transformed to an active"}, {"to": "973", "prefix": "ansformed to an active sulfenamide. When studied in  vitro, ", "from": "963", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is chemically activated at pH  1.2 with a half-life of 78  se"}, {"to": "2528", "prefix": "e-related decrease in intragastric acidity. The ability of ", "from": "2518", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " to cause a dose-related decrease in mean intragastric acidi"}, {"to": "8887", "prefix": " \n\n\nPatients with persistent H.  pylori infection following ", "from": "8877", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", amoxicillin, and clarithromycin therapy will likely have c"}, {"to": "10560", "prefix": " of ", "from": "10550", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " occur over a range of 2.0 to 5.0  hours "}, {"to": "10623", "prefix": ". The ", "from": "10613", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " Cmax and AUC are linear over an oral dose range of 10  mg to"}, {"to": "10825", "prefix": "g are administered every 24  hours; the pharmacokinetics of ", "from": "10815", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is not altered by multiple dosing.\n                        "}, {"to": "10988", "prefix": "ption: Absolute bioavailability for a 20  mg oral tablet of ", "from": "10978", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " "}, {"to": "11257", "prefix": " to 4  hours or longer. However, the Cmax and the extent of ", "from": "11247", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " absorption "}, {"to": "11588", "prefix": " of ", "from": "11578", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was 2.5  hours and ranged 1.0 to 6.5  hours. The plasma half-"}, {"to": "11667", "prefix": "hours and ranged 1.0 to 6.5  hours. The plasma half-life of ", "from": "11657", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " ranges from 1 to 2  hours.\n                        In health"}, {"to": "11802", "prefix": "lts, a concomitant high fat meal delayed the absorption of ", "from": "11792", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " from ACIPHEX granules sprinkled on one Tablespoon of apples"}, {"to": "12368", "prefix": "ft food did not significantly affect Tmax, Cmax and AUC of ", "from": "12358", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ".\n                        \n                           Distri"}, {"to": "12447", "prefix": "                 \n                           Distribution: ", "from": "12437", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is 96.3% bound to human plasma proteins.\n                  "}, {"to": "12564", "prefix": "                   \n                           Metabolism: ", "from": "12554", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is extensively metabolized. A significant portion of rabepr"}, {"to": "12629", "prefix": "azole is extensively metabolized. A significant portion of ", "from": "12619", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is metabolized via systemic nonenzymatic reduction to a thi"}, {"to": "12717", "prefix": "a systemic nonenzymatic reduction to a thioether compound. ", "from": "12707", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is also metabolized to sulphone and desmethyl compounds via"}, {"to": "13020", "prefix": "ecretory activity. In  vitro studies have demonstrated that ", "from": "13010", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is metabolized in the liver primarily by cytochromes P450 3"}, {"to": "13174", "prefix": " to desmethyl ", "from": "13164", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ". CYP2C19 exhibits a known genetic polymorphism due to its d"}, {"to": "13333", "prefix": ". ", "from": "13323", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " metabolism is slow in these sub-populations, therefore, the"}, {"to": "13571", "prefix": "ination: Following a single 20  mg oral dose of 14C-labeled ", "from": "13561", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", approximately 90% of the drug was eliminated in the urine,"}, {"to": "13844", "prefix": "s. Total recovery of radioactivity was 99.8%. No unchanged ", "from": "13834", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was recovered in the urine or feces.\n                      "}, {"to": "14006", "prefix": "riatric: In 20  healthy elderly subjects administered 20  mg ", "from": "13996", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " tablet once daily for seven days, AUC values approximately "}, {"to": "14373", "prefix": "                        Pediatric: The pharmacokinetics of ", "from": "14363", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was studied in pediatric patients with GERD aged up to 16  y"}, {"to": "14640", "prefix": "          \n                        The pharmacokinetics of ", "from": "14630", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was studied in 12  adolescent patients with GERD 12 to 16  ye"}, {"to": "14765", "prefix": "16  years of age, in a multicenter study. Patients received ", "from": "14755", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " 20  mg tablets once daily for five or seven days. An approxi"}, {"to": "15311", "prefix": "to 11  years of age, following once daily administration of ", "from": "15301", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " granules at doses from 0.14 to 1  mg"}, {"to": "15699", "prefix": "over the body weight range from 7 to 77.3  kg, the apparent ", "from": "15689", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " clearance increased from 8.0 to 13.5  L"}, {"to": "16273", "prefix": "r and Race: In analyses adjusted for body mass and height, ", "from": "16263", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " pharmacokinetics showed no clinically significant differenc"}, {"to": "16428", "prefix": "e subjects. In studies that used different formulations of ", "from": "16418", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", AUC0-"}, {"to": "16864", "prefix": "icant differences were observed in the pharmacokinetics of ", "from": "16854", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " after a single 20  mg oral dose when compared to 10  healthy "}, {"to": "17195", "prefix": "rrhosis of the liver who were administered a 20  mg dose of ", "from": "17185", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", AUC0-24 was approximately doubled, the elimination half-li"}, {"to": "17510", "prefix": "ith mild to moderate hepatic impairment administered 20  mg ", "from": "17500", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " once daily for eight days, AUC0-"}, {"to": "17765", "prefix": "nificant.\n                        No information exists on ", "from": "17755", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " disposition in patients with severe hepatic impairment. Ple"}, {"to": "18507", "prefix": "ed to values following single administration. However, the ", "from": "18497", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " AUC and Cmax increased by 11% and 34%, respectively, follow"}, {"to": "18765", "prefix": "by 42% and 46%, respectively. This increase in exposure to ", "from": "18755", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and 14-hydroxyclarithromycin is not expected to produce saf"}, {"to": "1564", "prefix": " begins within one hour after oral administration of 20  mg ", "from": "1558", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ". The median inhibitory effect of ACIPHEX on 24-hour gastric"}, {"to": "1605", "prefix": "stration of 20  mg ACIPHEX. The median inhibitory effect of ", "from": "1599", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " on 24-hour gastric acidity is 88% of maximal after the firs"}, {"to": "1680", "prefix": "ur gastric acidity is 88% of maximal after the first dose. ", "from": "1674", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg inhibits basal and peptone meal-stimulated acid secre"}, {"to": "2141", "prefix": "        \n\n\n                        \n\n\nCompared to placebo, ", "from": "2135", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ", 10  mg, 20  mg, and 40  mg, administered once daily for 7  day"}, {"to": "2705", "prefix": "\n\n                        \n\n\nAfter administration of 20  mg ", "from": "2699", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets once daily for eight days, the mean percent of time"}, {"to": "3003", "prefix": "acidity and the increase in gastric pH observed with 20  mg ", "from": "2997", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets administered once daily for eight days were compare"}, {"to": "3403", "prefix": " and moderate to severe esophageal acid exposure, ", "from": "3397", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg and 40  mg Tablets per day decreased 24-hour esophagea"}, {"to": "3838", "prefix": "riod; this level was achieved in 90% of subjects receiving ", "from": "3832", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg and in 100% of subjects receiving ACIPHEX 40  mg. With"}, {"to": "3886", "prefix": " receiving ACIPHEX 20  mg and in 100% of subjects receiving ", "from": "3880", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 40  mg. With ACIPHEX 20  mg and 40  mg per day, significant ef"}, {"to": "3906", "prefix": "0  mg and in 100% of subjects receiving ACIPHEX 40  mg. With ", "from": "3900", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg and 40  mg per day, significant effects on gastric and"}, {"to": "4237", "prefix": " \n                        In patients given daily doses of ", "from": "4231", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " for up to eight weeks to treat ulcerative or erosive esopha"}, {"to": "4578", "prefix": "                 In a group of subjects treated daily with ", "from": "4572", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg tablets for 4  weeks, a doubling of mean serum gastrin"}, {"to": "5433", "prefix": "\n                        In over 400  patients treated with ", "from": "5427", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets "}, {"to": "6075", "prefix": " endocrine system. In healthy male volunteers treated with ", "from": "6069", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " for 13  days, no clinically relevant changes have been detec"}, {"to": "6714", "prefix": "           \n                        In humans treated with ", "from": "6708", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " for up to one year, no systemic effects have been observed "}, {"to": "6936", "prefix": "systems. No data are available on long-term treatment with ", "from": "6930", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " and ocular effects.\n                        \n              "}, {"to": "7197", "prefix": " clinical significance is unknown.\n                        ", "from": "7180", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole sodium", "suffix": ", amoxicillin, and clarithromycin as a three drug regimen ha"}, {"to": "10239", "prefix": "macokinetics\n                     \n                        ", "from": "10233", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Delayed-Release Tablets and Delayed-Release granules in the"}, {"to": "10366", "prefix": "les in the capsule formulation are enteric-coated to allow ", "from": "10349", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole sodium", "suffix": ", which is acid labile, to pass through the stomach relative"}, {"to": "10503", "prefix": "                        After oral administration of 20  mg ", "from": "10497", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " tablet, peak plasma concentrations "}, {"to": "11064", "prefix": " is approximately 52%. When ", "from": "11058", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets are administered with a high fat meal, Tmax is vari"}, {"to": "11318", "prefix": " are not significantly altered. Thus ", "from": "11312", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets may be taken without regard to timing of meals.\n   "}, {"to": "11459", "prefix": "      After oral administration to healthy adults of 10  mg ", "from": "11453", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules sprinkled on applesauce under fasting condition, m"}, {"to": "11815", "prefix": "t high fat meal delayed the absorption of rabeprazole from ", "from": "11809", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules sprinkled on one Tablespoon of applesauce resultin"}, {"to": "11993", "prefix": "Cmax, and AUClast on average by 55% and 33%, respectively. ", "from": "11987", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules should be taken before a meal.\n                   "}, {"to": "12076", "prefix": "be taken before a meal.\n                        When 10  mg ", "from": "12070", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules administered under fasting conditions to healthy a"}, {"to": "15863", "prefix": " estimated total exposure, i.e., AUC after a 10  mg dose of ", "from": "15857", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Sprinkle in patients with GERD 1 to 11  years of age, is com"}, {"to": "15957", "prefix": "ERD 1 to 11  years of age, is comparable to a 10  mg dose of ", "from": "15951", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets in adolescents and adults.\n                        "}, {"to": "18167", "prefix": "sive metabolizers with respect to CYP2C19 were given 20  mg ", "from": "18150", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole sodium", "suffix": ", 1000  mg amoxicillin, 500  mg clarithromycin, or all 3  drugs"}, {"to": "19182", "prefix": "on of clopidogrel 75  mg concomitantly with placebo or with ", "from": "19176", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg "}, {"to": "19376", "prefix": " when ", "from": "19370", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " was coadministered compared to administration of clopidogre"}, {"to": "348", "prefix": "substituted ", "from": "336", "name": "benzimidazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C031000", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "benzimidazole", "suffix": " proton-pump inhibitors"}, {"to": "421", "prefix": " that do not exhibit anticholinergic or ", "from": "413", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "histamine", "suffix": " H2-receptor antagonist properties, but suppress gastric aci"}, {"to": "6201", "prefix": "-", "from": "6193", "name": "Estradiol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004958", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "estradiol", "suffix": ", thyroid stimulating hormone, tri-iodothyronine, thyroxine,"}, {"to": "6230", "prefix": "-estradiol, ", "from": "6204", "name": "Thyrotropin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013972", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "thyroid stimulating hormone", "suffix": ", tri-iodothyronine, thyroxine, thyroxine-binding protein, p"}, {"to": "6260", "prefix": "estradiol, thyroid stimulating hormone, tri-iodothyronine, ", "from": "6252", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "thyroxine", "suffix": ", thyroxine-binding protein, parathyroid hormone, insulin, g"}, {"to": "6271", "prefix": "thyroid stimulating hormone, tri-iodothyronine, thyroxine, ", "from": "6263", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "thyroxine", "suffix": "-binding protein, parathyroid hormone, insulin, glucagon, re"}, {"to": "6308", "prefix": ", tri-iodothyronine, thyroxine, thyroxine-binding protein, ", "from": "6290", "name": "Parathyroid Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D010281", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "parathyroid hormone", "suffix": ", insulin, glucagon, renin, aldosterone, follicle-stimulatin"}, {"to": "6317", "prefix": "thyroxine, thyroxine-binding protein, parathyroid hormone, ", "from": "6311", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "insulin", "suffix": ", glucagon, renin, aldosterone, follicle-stimulating hormone"}, {"to": "6327", "prefix": ", thyroxine-binding protein, parathyroid hormone, insulin, ", "from": "6320", "name": "Glucagon", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4832", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "glucagon", "suffix": ", renin, aldosterone, follicle-stimulating hormone, luteotro"}, {"to": "6347", "prefix": "ng protein, parathyroid hormone, insulin, glucagon, renin, ", "from": "6337", "name": "Aldosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000450", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "aldosterone", "suffix": ", follicle-stimulating hormone, luteotrophic hormone, prolac"}, {"to": "6377", "prefix": "arathyroid hormone, insulin, glucagon, renin, aldosterone, ", "from": "6350", "name": "Follicle Stimulating Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D005640", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "follicle-stimulating hormone", "suffix": ", luteotrophic hormone, prolactin, somatotrophic hormone, de"}, {"to": "6410", "prefix": "erone, follicle-stimulating hormone, luteotrophic hormone, ", "from": "6402", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prolactin", "suffix": ", somatotrophic hormone, dehydroepiandrosterone, cortisol-bi"}, {"to": "6457", "prefix": "e, luteotrophic hormone, prolactin, somatotrophic hormone, ", "from": "6436", "name": "Dehydroepiandrosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D003687", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "dehydroepiandrosterone", "suffix": ", cortisol-binding globulin, and urinary 6"}, {"to": "6467", "prefix": " prolactin, somatotrophic hormone, dehydroepiandrosterone, ", "from": "6460", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cortisol", "suffix": "-binding globulin, and urinary 6"}, {"to": "6559", "prefix": "-hydroxycortisol, serum testosterone and circadian ", "from": "6552", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cortisol", "suffix": " profile.\n                        \n                         "}, {"to": "6536", "prefix": "-hydroxycortisol, serum ", "from": "6525", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "testosterone", "suffix": " and circadian cortisol profile.\n                        \n  "}, {"to": "7210", "prefix": "gnificance is unknown.\n                        Rabeprazole ", "from": "7192", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "sodium, amoxicillin", "suffix": ", and clarithromycin as a three drug regimen has been shown "}, {"to": "7640", "prefix": "eptibility testing of H. pylori isolates was performed for ", "from": "7630", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " and clarithromycin using agar dilution methodology,1 and mi"}, {"to": "8491", "prefix": " to ", "from": "8481", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " at baseline. Two patients had baseline H.  pylori isolates w"}, {"to": "8569", "prefix": "line. Two patients had baseline H.  pylori isolates with an ", "from": "8559", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " MIC of 0.5  "}, {"to": "8764", "prefix": " section in prescribing information for clarithromycin and ", "from": "8754", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ".\n\n                        \n\n\n                        \n\n\nPat"}, {"to": "8900", "prefix": "with persistent H.  pylori infection following rabeprazole, ", "from": "8890", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ", and clarithromycin therapy will likely have clarithromycin"}, {"to": "9279", "prefix": "tuted.\n                        \n                           ", "from": "9269", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Amoxicillin", "suffix": " Susceptibility Test Results and Clinical"}, {"to": "9511", "prefix": " to ", "from": "9501", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " at baseline. The other 2  patients had baseline H.  pylori is"}, {"to": "9597", "prefix": "e other 2  patients had baseline H.  pylori isolates with an ", "from": "9587", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " MIC of 0.5  "}, {"to": "9853", "prefix": ", respectively, of the patients who had pretreatment ", "from": "9843", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " susceptible MICs "}, {"to": "9948", "prefix": " were eradicated of H.  pylori. No patients developed ", "from": "9938", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": "-resistant H.  pylori during therapy.\n                     \n "}, {"to": "18188", "prefix": "ct to CYP2C19 were given 20  mg rabeprazole sodium, 1000  mg ", "from": "18178", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ", 500  mg clarithromycin, or all 3  drugs in a four-way crosso"}, {"to": "18377", "prefix": " daily for 6  days. The AUC and Cmax for clarithromycin and ", "from": "18367", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " were not different following combined administration compar"}, {"to": "7230", "prefix": "                      Rabeprazole sodium, amoxicillin, and ", "from": "7217", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " as a three drug regimen has been shown to be active against"}, {"to": "7659", "prefix": "ng of H. pylori isolates was performed for amoxicillin and ", "from": "7646", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " using agar dilution methodology,1 and minimum inhibitory co"}, {"to": "8236", "prefix": "      Pretreatment Resistance:\n                            ", "from": "8223", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clarithromycin", "suffix": " pretreatment resistance rate "}, {"to": "8748", "prefix": "i, see Microbiology section in prescribing information for ", "from": "8735", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " and amoxicillin.\n\n                        \n\n\n              "}, {"to": "8920", "prefix": ".  pylori infection following rabeprazole, amoxicillin, and ", "from": "8907", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " therapy will likely have clarithromycin resistant clinical "}, {"to": "8960", "prefix": ", amoxicillin, and clarithromycin therapy will likely have ", "from": "8947", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " resistant clinical isolates. Therefore, clarithromycin susc"}, {"to": "9015", "prefix": "ave clarithromycin resistant clinical isolates. Therefore, ", "from": "9002", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " susceptibility testing should be done when possible. If res"}, {"to": "9100", "prefix": "ity testing should be done when possible. If resistance to ", "from": "9087", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " is demonstrated or susceptibility testing is not possible, "}, {"to": "9653", "prefix": "mL, and both isolates were ", "from": "9640", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": "-resistant at baseline; in one case the H.  pylori was eradic"}, {"to": "18211", "prefix": "iven 20  mg rabeprazole sodium, 1000  mg amoxicillin, 500  mg ", "from": "18198", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": ", or all 3  drugs in a four-way crossover study. Each of the "}, {"to": "18361", "prefix": " administered twice daily for 6  days. The AUC and Cmax for ", "from": "18348", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " and amoxicillin were not different following combined admin"}, {"to": "18678", "prefix": "active metabolite of ", "from": "18665", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": ""}, {"to": "13709", "prefix": "imarily as thioether carboxylic acid, its glucuronide, and ", "from": "13694", "name": "Acetylcysteine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000111", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "mercapturic acid", "suffix": " metabolites. The remainder of the dose was recovered in the"}, {"to": "16743", "prefix": "", "from": "16734", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "creatinine", "suffix": " clearance "}, {"to": "18241", "prefix": "mg amoxicillin, 500  mg clarithromycin, or all 3  drugs in a ", "from": "18234", "name": "Four-Way", "fullId": "http://purl.bioontology.org/ontology/RXNORM/217206", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "four-way", "suffix": " crossover study. Each of the four regimens was administered"}, {"to": "18922", "prefix": "          \n                           Concomitant Use with ", "from": "18912", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clopidogrel", "suffix": ": Clopidogrel is metabolized to its active metabolite in par"}, {"to": "18935", "prefix": "                         Concomitant Use with Clopidogrel: ", "from": "18925", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clopidogrel", "suffix": " is metabolized to its active metabolite in part by CYP2C19."}, {"to": "19133", "prefix": "ediate metabolizers receiving once daily administration of ", "from": "19123", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " 75  mg concomitantly with placebo or with ACIPHEX 20  mg "}, {"to": "19275", "prefix": "ys was conducted. The mean AUC of the active metabolite of ", "from": "19265", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " was reduced by approximately 12% "}, {"to": "19437", "prefix": "n ACIPHEX was coadministered compared to administration of ", "from": "19427", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " with placebo.\n                     \n                     \n "}]